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Abstract
AIM: To investigate the long-term results of liver 
transplantation (LT) for non-acetaminophen fulminant 
hepatic failure (FHF).
METHODS: Over a 20-year period, 29 FHF patients 
underwent cadaveric whole LT. Most frequent causes 
of FHF were hepatitis B virus and drug-related (not 
acetaminophen) liver failure. All surviving patients were 
regularly controlled at the out-patient clinic and none 
was lost to follow-up. Mean follow-up was 101 mo.
RESULTS: One month, one-, fi ve- and ten-year patient 
survival was 79%, 72%, 68% and 68%, respectively. 
One month, one-, fi ve- and ten-year graft survival was 
69%, 65%, 51% and 38%, respectively. Six patients 
needed early (< 2 mo) retransplantation, four for 
primary non-function, one for early acute refractory 
rejection because of ABO blood group incompatibility, 
and one for a malignant tumor found in the donor. 
Two patients with hepatitis B FHF developed cerebral 
lesions peri-transplantion: one developed irreversible 
and extensive brain damage leading to death, and one 
suffered from deep defi cits leading to continuous medical 
care in a specialized institution. 
CONCLUSION: Long-term outcome of pat ients 
transplanted for non-acetaminophen FHF may be 
excellent. As the quality of life of these patients is also 
particularly good, LT for FHF is clearly justifi ed, despite 
lower graft survival compared with LT for other liver 
diseases.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Fulminant hepatic failure (FHF) is a rare but a dreadful 
disease affecting mostly young patients. FHF is mainly 
managed based on symptoms, the identification of  the 
FHF causes requiring specific treatment and supportive 
care, as FHF patients have chances of  recovery[1]. The 
main causes of  death of  FHF patients are intracranial 
hypertension leading to brain stem death, and sepsis 
with multiple organ failure (MOF)[2]. Many liver support 
systems have been tried, but the ideal and effi cient artifi cial 
liver has still to be designed and its effi cacy to be proven[3]. 
In the sickest cases, when established predicting factors 
of  death are reached, liver transplantation (LT) has been 
established as the standard treatment for FHF patients[4]. 
However, the results of  LT for FHF may be disappointing, 
especially compared with the results of  LT for chronic liver 
diseases since FHF patients often suffer from risk factors 
for graft failure or high morbidity or/and mortality[5].
In the United States of  America (USA) and in the 
United Kingdom (UK), FHF is very frequently caused 
by acetaminophen intoxication[6-9]. However this etiology 
is far less frequent in other Western countries. The aim 
of  this study is to report the 20-year experience and the 
results of  LT for non-acetaminophen FHF of  the liver 
transplantation program of  the University of  Liège, 
Belgium, a transplantation center working within the 
Eurotransplant allocation system. As many variables 
changed during such a long period of  time, the authors 
focused this report on the outcome of  FHF patients who 
underwent LT.
MATERIALS AND METHODS
The liver transplantation program of  the University of  
Liège started in 1986[10]. From 1986 to December 2005, 
345 cases of  LT were performed, mostly in adult patients, 
including 7 adult-to-adult living-related LT[11]. Among this 
series, 58 patients were listed for Hyper Urgent (HU) LT, 
meaning patients with FHF, or patients requiring urgent 
retransplantation for primary non-function (PNF) or 
vascular thrombosis after LT. Thirty-two patients were 
registered for FHF. All these patients were suffering from 
FHF as defined by the occurrence of  encephalopathy 
within 8 wk after jaundice development in patients without 
previous histories of  liver disease[12]. All reached the 
established criteria for bad prognosis as established by the 
Clichy’ s group (non-acetaminophen FHF group) or the 
King’s College (acetaminophen FHF group)[13,14]. Three 
patients who suffered from acetaminophen FHF and who 
met the King’s College criteria for bad prognosis, recovered 
under medical therapy and intravenous N-acetylcysteine 
therapy. They were removed for subsequent analysis. 
All patients were hospitalized in the intensive care 
unit and underwent standard medical therapy[1]. None 
but one patient received liver support with the Molecular 
Adsorbents Recirculating System (MARS). Patients 
in encephalopathy stage Ⅲ were intubated for airway 
protection, if  necessary. Continuous veno-venous 
hemofiltration was used for renal support. No patient 
underwent intracranial pressure monitoring.
All patients were registered for HU cadaveric LT 
in the Eurotransplant allocation system. Until 1992, 
transplantation of  an ABO non-compatible liver graft was 
authorized for recipient life–saving purpose. As results 
of  the non-compatible LT were not satisfactory in terms 
of  graft survival, ABO compatible LT was required after 
1992. All patients were transplanted with cadaveric whole 
liver. Orthotopic whole LT with veno-venous bypass was 
performed as the standard LT procedure from 1986 to 
1994. After 1995 the standard surgical procedure for LT 
was the Belghiti’s technique, i.e. a piggy-back LT with 
temporary surgical porto-caval shunt, without use of  
veno-venous bypass and with large cavo-caval side-to-
side anastomosis as venous reconstruction[15,16]. During 
this 20-year period, many other variables changed in the 
management of  patients with FHF and of  LT recipients. 
Immunosuppressive protocols in triple therapy regimens 
included cyclosporine/tacrolimus, Imuran/Cellcept and 
steroids. Steroids were progressively weaned, and most 
patients were under calcineurin inhibitor monotherapy at 
one-year follow-up. Patients transplanted for hepatitis B 
virus (HBV) FHF received life-long immunoprophylaxis 
with intravenous anti-HBs antibodies (10 000 UI every 3-4 
mo, aiming at a minimum blood level > 100 mUI/mL).
All surviving patients were regularly controlled at the 
out-patient clinic and none was lost to follow-up. Mean 
follow-up was 101 mo (range: 5–204 mo). Statistical 
analysis was undertaken using patient and graft survival 
as endpoints. Survival was calculated using the method of  
    Causes                                           No.
Viral infection                                                 12 (HBV: 11, HAV: 1)
Drug induced                                                   5
Miscellaneous                                                   7
   Budd-Chiari                                                   1
   Wilson                                                             2
   Ischemic                                                          2
   Alcohol                                                            1
   Autoimmune                                                  1
Undetermined                                                   5
Table 1  Causes of fulminant hepatic failure in this series
HBV: hepatitis B virus; HAV: hepatitis A virus.
Kaplan-Meier.
RESULTS
Twenty-nine patients (nine males, twenty females; mean 
age 39 years, range: 14–66 years) who developed non-
acetaminophen FHF, were listed for cadaveric LT and 
underwent transplantation. The etiology of  FHF is 
presented in Table 1. Most frequent causes of  FHF 
in this group were hepatitis B virus (HBV) and drug-
related. Three patients were in encephalopathy stage Ⅱ, 
10 in stage Ⅲ and 16 in stage Ⅳ, at time of  LT listing. 
Mean factor Ⅴ level was 16% (range: 5%-31%). Mean 
waiting time between listing for HU LT and availability 
of  a liver graft was 23 h (range: 4–49 h). Twenty patients 
were mechanically ventilated at time of  listing and until 
LT. Nineteen developed acute renal failure and needed 
hemofiltration. Mean cadaveric donor age was 40 years 
(range: 14-57 years). Mean total graft ischemia was 417 
min (range: 245-750 min). One month, one-, fi ve- and ten-
year survival was 79%, 72%, 68% and 68%, respectively 
(Figure 1). All patients who survived the first two years 
were alive at follow-up. Causes of  early death (< 2 mo) 
were MOF, PNF (1 case) and peri-operative brain death 
(1 case). The only patient who died after 2 mo was not 
compliant to medical therapy after transplantation, 
suffered from chronic allograft rejection but was denied 
















Graft and Patient Survival after LT for FHF
Figure 1  Patient and graft survivals after liver transplantation for fulminant hepatic 
failure according to the Kaplan-Meier method. 
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for re-transplantation (died at 18 mo of  follow-up).
Six patients needed early (< 2 mo) re-LT, 4 for PNF, 1 
for early acute refractory rejection because of  ABO blood 
group incompatibility, and 1 for a malignant tumor found 
in the donor[17]. Three patients needed late (> 2 mo) re-
tranplantation due to chronic rejection or chronic graft 
dysfunction due to ABO blood group incompatibility 
in two cases and to non-compliance in one case. One 
patient needed a third transplantation because of  chronic 
cholangitis on the second graft. One month, one-, five- 
and ten-year graft survival was 69%, 65%, 51% and 38%, 
respectively (Figure 1). 
In the group of  long-term survivors, two young females 
later enjoyed a total of  three normal pregnancies. Among 
the patients transplanted for HBV FHF, one developed 
HBV graft reinfection treated first by lamivudine, and 
afterwards adefovir when the virus became resistant to 
lamivudine. This patient is well at follow-up, with graft 
fi brosis at biopsy. Two patients with HBV FHF, developed 
cerebral lesions during the peri-transplantation period: one 
developed irreversible and extensive brain damage leading 
to death, and one suffered from deep defi cits leading to 
the continuous medical care in a specialized institution.
DISCUSSION
FHF is nowadays a well-admitted indication for urgent 
liver transplantation if  the King’s College or Clichy’
s criteria are met. According to the European Liver 
Transplant Registry (www.eltr.org), 9% of  the LT 
performed in Europe are performed for FHF. In our 
experience at the University of  Liège, FHF represents 8.5% 
of  the indications of  LT. If  acetaminophen intoxication 
is one of  the main indications in the USA and UK, this 
etiology is rare in other Western countries. In the authors’ 
experience, only three patients were listed for LT because 
of  liver failure due to acetaminophen overdose in a 20-year 
period, and these three patients recovered on medical 
therapy including intravenous N-acetylcysteine, while listed 
for urgent LT. It is therefore important to assess the results 
of  LT in patients with liver failure due to other causes, 
to confirm long-term survival despite a very unstable 
medical condition at the time of  listing and at the time of  
transplantation. This is the case, as 68% of  the patients 
transplanted for FHF were alive at the 10-year follow-up.
In our experience, HBV infection represents the 
main cause of  FHF leading to LT (38%). In the 1990’
s, systematic vaccination against HBV was initiated in 
Belgium. This policy reduced the frequency of  HBV 
FHF in the native population, but recent immigrants still 
face HBV-related FHF. Drug-related FHF represents the 
second identifi ed cause of  FHF in this series (17%), and 
in fi ve other cases we were not able to defi ne the causative 
factor, as it was frequently reported in other series[18].
In our series the patients who underwent LT for FHF 
enjoyed excellent long-term survival, 68% of  them were 
alive and well at 10-year follow-up. These results compare 
favorably to other series of  the literature[4,13,18-21]. Moreover, 
as our experienced showed, if  the patients survived the 
peri-operative period, they would have a good hope of  
survival with a low risk of  late death. They also enjoy a 
very good quality of  life with a low risk of  liver disease 
recurrence or chronic rejection if  they are compliant to the 
medical treatment. However, these good results in terms 
of  graft survival are obtained at the price of  a high rate 
of  re-transplantation, as graft survival rate was 38% at 10 
years.
The main cause of  death in our series was MOF. This is 
certainly linked to medical status of  these instable patients 
who often suffered from kidney and respiratory failure at 
the time of  transplantation. This is also related to the high 
rate of  PNF and the urgency for LT in this indication. This 
series also showed the efficiency of  the Eurotransplant 
organization in providing rapidly a cadaveric liver graft 
for these urgent patients. In the early period of  this 
experience, transplantation of  an ABO uncompatible graft 
was allowed as a life-saving bridge to a later compatible 
graft. However, this policy was not prolonged because it 
consumes two grafts at a time of  organ shortage. However, 
the change of  policy did not have a signifi cant impact on 
the waiting time of  these urgent patients, and to our view, 
there is no need for a living-related liver program for FHF 
in resident patients within the Eurotransplant area. In 
recent series of  the literature, creatinine levels, body mass 
index, recipient age and history of  life support have been 
established as signifi cant risk factors for post-LT death in 
FHF patients[5,18].
At least two pat ients of  this ser ies developed 
neurological lesions during the peri-transplantation 
period. This is certainly due to intracranial hypertension, 
a frequent complication of  FHF, promoted by brain 
edema and increased blood fl ow[2]. We demonstrated that 
during LT for FHF the dissection and reperfusion phases 
are particularly at risk of  intracranial hypertension[22]. 
On the contrary, the anhepatic phase, even if  prolonged, 
may be associated with good neurologic outcome[23]. The 
development of  neurological lesions during the peri-
transplantation period has also been reported in larger 
series[18,24]. 
In conclusion, this series confirmed that long-term 
outcome of  patients transplanted for non-acetaminophen 
FHF may be excellent. As the quality of  life of  these 
patients is also particularly good, these results proved that 
LT for FHF is clearly justifi ed, despite lower graft survival 
compared to LT for other liver diseases.
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